Results 231 to 240 of about 1,323,182 (282)

Optimizing Efficacy to Safety Ratio of Glucocorticoids in Rheumatoid Arthritis Models by Leveraging Peroxisome Proliferator–Activated Nuclear Receptor‐α Agonism

open access: yesArthritis &Rheumatology, EarlyView.
Objective Glucocorticoids remain essential therapies for immune and inflammatory diseases such as rheumatoid arthritis (RA) but are notorious for their metabolic side effects. Given the anti‐inflammatory and metabolically favorable actions of peroxisome proliferator–activated nuclear receptor (PPAR) agonists, we investigated whether PPARα agonism could
Lisa L. Koorneef   +17 more
wiley   +1 more source

Human Monocytic Models Reveal Genotype‐Dependent Inflammatory Programs in VEXAS Syndrome

open access: yesArthritis &Rheumatology, EarlyView.
Objective VEXAS syndrome is a severe X‐linked autoinflammatory disorder caused by somatic mutations in ubiquitin‐like modifier activating enzyme 1 (UBA1), with clinical outcomes that vary by UBA1 genotype. We aimed to elucidate genotype‐specific inflammatory programs and identify potential therapeutic targets.
Kana Higashitani   +10 more
wiley   +1 more source

REACTIVE ARTHRITIS

Scandinavian Journal of Rheumatology, 2005
Reactive arthritis (ReA) was known as Reiter's disease or Fiessinger-Leroy disease for nearly 100 years. However, during the past 30 years the disease has been known as reactive arthritis, a member of the spondyloarthritis family. Despite knowing the initiating event (infection) and genetic constitution (many patients have HLA-B27) of ReA, a model of ...
Rubén Burgos-Vargas   +1 more
  +6 more sources

Reactive arthritis

Current Opinion in Rheumatology, 1999
Reactive arthritis is one of the spondyloarthropathy family of clinical syndromes. The clinical features are those shared by other members of the spondyloarthritis family, though it is distinguished by a clear relationship with a precipitating infection.
J, Sieper, J, Braun
openaire   +4 more sources

Reactive arthritis

Current Opinion in Rheumatology, 1996
The complex interactions between the triggering microbe and the defense mechanisms of the host in reactive arthritis have been studied in several laboratories around the world, and interesting observations have been made. Research has also focused on the mediators in the inflammatory process in joints, and these results are helping to slowly build a ...
A, Toivanen, P, Toivanen
openaire   +7 more sources

REACTIVE ARTHRITIS

Annual Review of Medicine, 1987
Inflammatory arthritis occurring days to weeks after a localized infection is known as reactive arthritis. Epidemiologic, genetic, and immunologic features have established this disease as a distinct clinicopathologic entity. Although reactive arthritis is often a transient disease, many individuals suffer a chronic relapsing course.
G S, Firestein, N J, Zvaifler
openaire   +2 more sources

Reactive Arthritis

Infectious Disease Clinics of North America, 2017
Reactive arthritis is classified as a spondyloarthropathy. Current concepts of disease suggest an infectious trigger, followed by inflammatory arthritis. Several mechanisms have been proposed to explain the interaction of host susceptibility and microorganism.
Steven K Schmitt
exaly   +3 more sources

Reactive Arthritis

Journal of the European Academy of Dermatology and Venereology, 2014
AbstractReactive arthritis (ReA) is an immune‐mediated seronegative arthritis that belongs to the group of spondyloarthropathies and develops after a gastrointestinal or genitourinary system infection. The condition is considered to be characterized by a triad of symptoms (conjunctivitis, arthritis and urethritis) although a constellation of other ...
P G, Stavropoulos   +4 more
openaire   +2 more sources

Reactive Arthritis: A Review

Journal of Adolescent Health, 2009
This review article summarizes the available literature on adolescent reactive arthritis. A review of the pathophysiology, diagnosis, and treatment guidelines will be helpful to better diagnose and treat reactive arthritis.
Paul S, Kim   +2 more
exaly   +3 more sources

Home - About - Disclaimer - Privacy